2021 American Transplant Congress
Pharmacokinetic and Toxicity Studies of an Anti CD40L Antibody, At-1501 in Rhesus Macaques
1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory receptor for CD40 found on T helper cells. Binding of CD40L on T cells to CD40 on antigen presenting cells…2021 American Transplant Congress
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of At-1501
1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA
*Purpose: Execute a phase 1 study of AT-1501 to assess safety, pharmacokinetics, and functional activity.*Methods: The study employed a placebo-controlled, sequential, dose-escalation design. 28 healthy…2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…2021 American Transplant Congress
Bamlanivimab for Covid-19 in Kidney Transplant Patients
Nephrology, Indiana University School of Medicine, Indianapolis, IN
*Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
1Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, 2Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…2021 American Transplant Congress
The Development and Characterization of AT1501, an Anti CD40L Antibody Lacking Fc Effector Function
1Novus Therapeutics, Irvine, CA, 2ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory type II membrane receptor for CD40. The binding of CD40L on T helper cells to CD40 on antigen presenting cells…2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…2020 American Transplant Congress
New Strategy to Maximize Nanomedicine Delivery During Ex Vivo Organ Perfusion
*Purpose: Organ transplant is a highly successful therapy for patients facing end stage organ failure. However, there is a severe lack of transplantable organs which…2020 American Transplant Congress
Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection
*Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…
- 1
- 2
- 3
- 4
- Next Page »